These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2892077)

  • 1. Reversal by intradermal hepatitis B vaccination of unresponsiveness to HBsAg.
    Nagafuchi S; Kashiwagi S
    Lancet; 1987 Dec; 2(8574):1522-3. PubMed ID: 2892077
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B vaccine: responder status and timing of additional booster doses.
    Fagan EA; Williams R; Eddleston AL
    Lancet; 1987 Sep; 2(8558):561. PubMed ID: 2887842
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of intradermal hepatitis B immunization of hospital staff.
    McKee CM; Duke P; McEvoy MB; Kelsey MC
    Int J STD AIDS; 1990 Jan; 1(1):32-4. PubMed ID: 2151564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen.
    Frazer IH; Jones B; Dimitrakakis M; Mackay IR
    Med J Aust; 1987 Mar; 146(5):242-5. PubMed ID: 2950303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term follow-up study of HBsAb titers in subjects given HB vaccine and timing for additional vaccination].
    Nakao M; Yamada H; Ono T; Kuroki T; Kobayashi K; Yamamoto S; Monna T
    Nihon Shokakibyo Gakkai Zasshi; 1988 Jan; 85(1):20-7. PubMed ID: 2967388
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical and immunological studies of an experimental series of vaccines against hepatitis B].
    Teokharova MP; Andonov AP; Mineva EG; Draganov PI
    Vopr Virusol; 1984; 29(4):483-7. PubMed ID: 6495708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Active hepatitis B immunization--current status of development and effectiveness].
    Baumgarten R; Fengler JD
    Z Arztl Fortbild (Jena); 1986; 80(10):393-4. PubMed ID: 2944291
    [No Abstract]   [Full Text] [Related]  

  • 8. [Specific safety and immunogenicity of a subunit vaccine against hepatitis B].
    Viazov SO; Vlasikhina EM; Margolina AN; Favorov MO; Poverennyĭ AM
    Vopr Virusol; 1985; 30(3):324-7. PubMed ID: 4049843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunisation against hepatitis B.
    Lancet; 1988 Apr; 1(8590):875-6. PubMed ID: 2895375
    [No Abstract]   [Full Text] [Related]  

  • 10. [Serologic indicators of the preventive activity of gamma globulin produced by the Warsaw Laboratory of Sera and Vaccines in 1972-1984 against viral hepatitis].
    Karwowska S; Kacperska E; Seyfried H; Nowosławski A
    Przegl Epidemiol; 1986; 40(2):193-9. PubMed ID: 2433711
    [No Abstract]   [Full Text] [Related]  

  • 11. Specific lymphocyte proliferative response in vitro after cDNA HBsAg immunization.
    Degrassi A; Mariani E; Roda P; Miniero R; Capelli M; Honorati MC; Astaldi A; Facchini A
    Adv Exp Med Biol; 1989; 257():237-45. PubMed ID: 2533459
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccination against hepatitis B in preschool children with Down's syndrome.
    Vajro P; Lettera P; Fontanella A; Sbreglia C; Manzillo E; Sartorio R; Del Giudice E
    J Intellect Disabil Res; 1992 Feb; 36 ( Pt 1)():77-81. PubMed ID: 1533557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose range study in healthy volunteers of a hepatitis B vaccine produced in yeast.
    Kuwert E; Scheiermann N; Gesemann M; Paar D; Safary A; Simoen E; Hauser P; Andre F
    Antiviral Res; 1985; Suppl 1():281-8. PubMed ID: 2935080
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical and serological evaluation of preventive vaccination of volunteers of the high risk group with hepatitis B vaccine].
    Brzosko WJ; Laskowski ZK; Bańkowski A; Janicki P; Dabrowa A; Tkacz B; Gall W
    Pol Tyg Lek; 1986 Jul; 41(28):893-5. PubMed ID: 2945170
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine.
    Zoulek G; Lorbeer B; Jilg W; Deinhardt F
    Lancet; 1984 Oct; 2(8409):983-4. PubMed ID: 6149374
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity and side effects of low dose intradermally administered hepatitis B vaccine.
    Pathak UN; Dilawari JB; Chawla Y; Sokhey CS; Sharma BK; Ganguly NK
    Indian J Gastroenterol; 1988 Apr; 7(2):113-4. PubMed ID: 2966113
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody response to heat-inactivated hepatitis B vaccine (CLB-3 micrograms) in hemodialysis patients and occupational risk personnel: a one year follow-up.
    Yoshida FT; Takahashi C; Mercadante LA; Camargo IF; Schatzmayr HG
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):11-6. PubMed ID: 2975824
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose intradermal and intramuscular vaccination against hepatitis B.
    Bryan JP; Sjogren MH; Perine PL; Legters LJ
    Clin Infect Dis; 1992 Mar; 14(3):697-707. PubMed ID: 1532914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine.
    Horowitz MM; Ershler WB; McKinney WP; Battiola RJ
    Ann Intern Med; 1988 Feb; 108(2):185-9. PubMed ID: 2963570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody to hepatitis B surface antigen and screening before hepatitis B vaccination.
    Kane MA; Hadler SC; Maynard JE
    Ann Intern Med; 1985 Nov; 103(5):791-3. PubMed ID: 2932046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.